

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5287373

|                              |                |
|------------------------------|----------------|
| <b>SUBMISSION TYPE:</b>      | NEW ASSIGNMENT |
| <b>NATURE OF CONVEYANCE:</b> | ASSIGNMENT     |

**CONVEYING PARTY DATA**

| Name            | Execution Date |
|-----------------|----------------|
| FEI SUN         | 10/19/2018     |
| LIFANG WU       | 10/19/2018     |
| CHARLES Z. DING | 10/19/2018     |
| GUOPING HU      | 10/19/2018     |
| JIAN LI         | 10/19/2018     |
| SHUHUI CHEN     | 10/19/2018     |
| JIANYU LU       | 10/19/2018     |

**RECEIVING PARTY DATA**

|                          |                                       |
|--------------------------|---------------------------------------|
| <b>Name:</b>             | GENFLEET THERAPEUTICS (SHANGHAI) INC. |
| <b>Street Address:</b>   | 1000 ZHANGHENG ROAD, SUITE 63         |
| <b>Internal Address:</b> | PUDONG NEW AREA                       |
| <b>City:</b>             | SHANGHAI                              |
| <b>State/Country:</b>    | CHINA                                 |
| <b>Postal Code:</b>      | 201203                                |
| <b>Name:</b>             | MEDSHINE DISCOVERY INC.               |
| <b>Street Address:</b>   | ROOM 218, NO.9 GAOXIN ROAD,           |
| <b>Internal Address:</b> | GAOXIN DEVELOPMENT DISTRICT           |
| <b>City:</b>             | NANJING, JIANGSU                      |
| <b>State/Country:</b>    | CHINA                                 |
| <b>Postal Code:</b>      | 210032                                |

**PROPERTY NUMBERS Total: 1**

| Property Type       | Number   |
|---------------------|----------|
| Application Number: | 16308859 |

**CORRESPONDENCE DATA**

Fax Number: (248)641-0270

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: (248) 641-1222

Email: troymailroom@hdp.com,jgrazia@hdp.com

**Correspondent Name:** HARNESS, DICKEY & PIERCE, P.L.C.  
**Address Line 1:** P.O. BOX 828  
**Address Line 4:** BLOOMFIELD HILLS, MICHIGAN 48303

**ATTORNEY DOCKET NUMBER:** 17424-000030-US-NP

**NAME OF SUBMITTER:** DONALD G. WALKER

**SIGNATURE:** /Donald G. Walker/

**DATE SIGNED:** 12/17/2018

**Total Attachments: 4**

source=17424-30-NP\_Declaration#page1.tif

source=17424-30-NP\_Declaration#page2.tif

source=17424-30-NP\_Declaration#page3.tif

source=17424-30-NP\_Declaration#page4.tif

## DECLARATION AND ASSIGNMENT<sup>1</sup>

The undersigned acknowledges that this document is being used both as an assignment of the invention and as the declaration (37 CFR 1.63) for a Utility or Design Application entitled:

TITLE:      Benzotriazole-Derived Alpha And Beta Unsaturated Amide Compound Used  
            As TGF-Beta R1 Inhibitor

As a below named inventor, I hereby declare that:

This declaration is directed to (check one):

- The attached application, or
- United States application or PCT international application number PCT/CN2017/087546  
filed on June 8, 2017.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the above-identified application.

I hereby acknowledge that any willful false statement made in this declaration and assignment is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

I hereby state that I have reviewed and understand the contents of the above-identified application, including the claims.

I acknowledge that I am aware of the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

For good and valuable consideration, the receipt and adequacy whereof I hereby acknowledge, I hereby confirm any prior assignment to **GENFLEET THERAPEUTICS (SHANGHAI) INC., 1000 Zhangheng Road, Suite 63, Pudong New Area, Shanghai 201203, PEOPLE'S REPUBLIC OF CHINA** and **MEDSHINE DISCOVERY INC., Room 218, No.9 Gaoxin Road, Gaoxin Development District Nanjing, Jiangsu 210032 PEOPLE'S REPUBLIC OF CHINA** (hereinafter "Assignee"), and to the extent that I have not already done so, agree to assign, and hereby do, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world,

---

<sup>1</sup> This form requires an ADS if one has not yet been filed.

including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in the above-identified application, to the above-identified application itself, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the above-identified application, and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid application and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by me had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights.

I hereby covenant and agree to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, any derivation proceedings relating thereto, and as to Letters Patent any supplemental examination, derivation proceeding, opposition, post grant review, reissue, re-examination, inter partes review, or extension thereof, and for litigation regarding, or for the purpose of protecting title and to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee without further or other compensation than that above set forth.

I hereby covenant that I have not made and will not make any assignment, sale, license, agreement or encumbrance which would conflict with this declaration and assignment.

I hereby request the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and request that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

I hereby grant the law firm of Harness, Dickey & Pierce, P.L.C. the power to insert on this declaration and assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

Fei Sun  
Fei SUN

\_\_\_\_\_  
Witness 1

October 19, 2018  
Dated


\_\_\_\_\_  
Witness 2

Lifang WU  
Lifang WU

\_\_\_\_\_  
Witness 1

October 19, 2018  
Dated


\_\_\_\_\_  
Witness 2

  
Charles Z. DING

\_\_\_\_\_  
Witness 1

October 19, 2018  
Dated


\_\_\_\_\_  
Witness 2

  
Guoping HU

\_\_\_\_\_  
Witness 1

October 19, 2018  
Dated


\_\_\_\_\_  
Witness 2

  
Jian LI

\_\_\_\_\_  
Witness 1

October 19, 2018  
Dated

\_\_\_\_\_  
Witness 2


  
\_\_\_\_\_  
Shuhui CHEN

October 19, 2018

\_\_\_\_\_  
Dated

\_\_\_\_\_  
Witness 1

\_\_\_\_\_  
Witness 2

  
\_\_\_\_\_  
Jianyu LI

October 19, 2018

\_\_\_\_\_  
Dated

\_\_\_\_\_  
Witness 1

\_\_\_\_\_  
Witness 2